Mitchell A. deLong

914 total citations
29 papers, 676 citations indexed

About

Mitchell A. deLong is a scholar working on Pharmacology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Mitchell A. deLong has authored 29 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 7 papers in Organic Chemistry and 7 papers in Molecular Biology. Recurrent topics in Mitchell A. deLong's work include Glaucoma and retinal disorders (7 papers), Flavonoids in Medical Research (5 papers) and Bone health and treatments (4 papers). Mitchell A. deLong is often cited by papers focused on Glaucoma and retinal disorders (7 papers), Flavonoids in Medical Research (5 papers) and Bone health and treatments (4 papers). Mitchell A. deLong collaborates with scholars based in United States, Canada and Taiwan. Mitchell A. deLong's co-authors include Raymond E. Boissy, Marty O. Visscher, Casey Kopczynski, Bryan W. Sherman, Cheng‐Wen Lin, Carmen Laethem, R. Randall Wickett, Ponugoti Vasantha Rao, Da‐Wen Lu and Padmanabhan P. Pattabiraman and has published in prestigious journals such as Biochemistry, Journal of Medicinal Chemistry and Archives of Biochemistry and Biophysics.

In The Last Decade

Mitchell A. deLong

26 papers receiving 651 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitchell A. deLong United States	11	221	207	187	128	124	29	676
Seung‐Yong Seo South Korea	19	53 0.2×	400 1.9×	56 0.3×	221 1.7×	21 0.2×	76	822
G. Graff United States	13	48 0.2×	288 1.4×	39 0.2×	68 0.5×	15 0.1×	27	660
Hong‐Sig Sin South Korea	14	37 0.2×	328 1.6×	7 0.0×	135 1.1×	59 0.5×	35	679
M. Dardalhon France	16	68 0.3×	510 2.5×	4 0.0×	43 0.3×	40 0.3×	37	872
Koichi Itakura Japan	12	52 0.2×	285 1.4×	7 0.0×	121 0.9×	7 0.1×	23	625
Boël Löfberg Sweden	15	19 0.1×	274 1.3×	11 0.1×	29 0.2×	13 0.1×	22	485
Jessica Ponder United States	12	81 0.4×	208 1.0×	30 0.2×	96 0.8×	2 0.0×	16	424
Marisa Cabeza Mexico	18	67 0.3×	404 2.0×	2 0.0×	123 1.0×	22 0.2×	82	940
Erik T. Bodor United States	10	37 0.2×	344 1.7×	6 0.0×	52 0.4×	6 0.0×	16	688

Countries citing papers authored by Mitchell A. deLong

Since Specialization

Citations

This map shows the geographic impact of Mitchell A. deLong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell A. deLong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell A. deLong more than expected).

Fields of papers citing papers by Mitchell A. deLong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell A. deLong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell A. deLong. The network helps show where Mitchell A. deLong may publish in the future.

Co-authorship network of co-authors of Mitchell A. deLong

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell A. deLong. A scholar is included among the top collaborators of Mitchell A. deLong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell A. deLong. Mitchell A. deLong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miller, Steven T., Robert V. Brown, Stuart Williams, et al.. (2023). Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility. Journal of Medicinal Chemistry. 66(13). 8929–8950. 4 indexed citations

Williams, Stuart, Mitchell A. deLong, Natalie Girouard, et al.. (2023). Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid Conjugates. Journal of Ocular Pharmacology and Therapeutics. 39(2). 117–127. 1 indexed citations

Kelly, Curtis R., et al.. (2022). Effects of Netarsudil-Family Rho Kinase Inhibitors on Human Trabecular Meshwork Cell Contractility and Actin Remodeling Using a Bioengineered ECM Hydrogel. Frontiers in Ophthalmology. 2. 948397–948397. 7 indexed citations

Zaretskaia, Maria V., Kevin Carbajal, Karen M. Crews, et al.. (2021). Ocular pharmacokinetics of a novel class of corticosteroids with ROCK inhibitory activity and potential for reduced steroid-associated risks. Investigative Ophthalmology & Visual Science. 62(8). 1292–1292.

Lin, Cheng‐Wen, Bryan W. Sherman, Carmen Laethem, et al.. (2017). Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. Journal of Ocular Pharmacology and Therapeutics. 34(1-2). 40–51. 132 indexed citations

Lin, Cheng‐Wen, et al.. (2016). Effectiveness of AR-13154 monotherapy and combination therapy in animal models of wet age-related macular degeneration and proliferative diabetic retinopathy. Investigative Ophthalmology & Visual Science. 57(12). 287–287. 2 indexed citations

Lin, Cheng‐Wen, Jeffrey D. Yingling, Carmen Laethem, et al.. (2016). Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorganic & Medicinal Chemistry Letters. 26(10). 2475–2480. 82 indexed citations

deLong, Mitchell A., et al.. (2012). DeoxyArbutin and its derivatives inhibit tyrosinase activity and melanin synthesis without inducing reactive oxygen species or apoptosis.. PubMed. 11(10). e28–34. 15 indexed citations

Yingling, Jeffrey D., John J. Arnold, Mitchell A. deLong, Cheng‐Wen Lin, & Casey Kopczynski. (2009). IOP-Lowering Efficacy and Tolerability of AR-12286, a Potent Kinase Inhibitor for the Treatment of Glaucoma. Investigative Ophthalmology & Visual Science. 50(13). 4063–4063. 3 indexed citations

10.

deLong, Mitchell A., et al.. (2008). Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives. British Journal of Dermatology. 159(6). 1267–1274. 50 indexed citations

11.

Miller, Laura A., Mitchell A. deLong, Lamar Galloway, et al.. (2003). Glutathione, S-substituted glutathiones, and leukotriene C4 as substrates for peptidylglycine α-amidating monooxygenase. Archives of Biochemistry and Biophysics. 412(1). 3–12. 7 indexed citations

12.

Milbank, Jared B. J., Glen E. Mieling, Robin L. Cooper, et al.. (2001). Synthesis and Biological Evaluation of Prostaglandin-F Alkylphosphinic Acid Derivatives as Bone Anabolic Agents for the Treatment of Osteoporosis.. Journal of Medicinal Chemistry. 44(24). 4307–4307.

13.

Milbank, Jared B. J., Glen E. Mieling, Andrew S. Kende, et al.. (2001). Synthesis and Biological Evaluation of Prostaglandin-F Alkylphosphinic Acid Derivatives as Bone Anabolic Agents for the Treatment of Osteoporosis. Journal of Medicinal Chemistry. 44(24). 4157–4169. 12 indexed citations

14.

Wang, Yili, et al.. (2000). The Synthesis and Human FP Receptor Binding Affinity of 13,14-Dihydro Prostaglandin F1.ALPHA. Sulfonamides. Potential Treatments for Osteoporosis.. Chemical and Pharmaceutical Bulletin. 48(9). 1332–1337. 25 indexed citations

15.

deLong, Mitchell A., et al.. (2000). Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues. Bioorganic & Medicinal Chemistry Letters. 10(14). 1519–1522. 5 indexed citations

16.

Eichhold, Thomas H., Timothy R. Baker, Jack Amburgey, et al.. (2000). Use of short high-performance liquid chromatography columns and tandem-mass spectrometry for the rapid analysis of a prostaglandin analog, fluprostenol, in rat plasma. Journal of Chromatography B Biomedical Sciences and Applications. 741(2). 213–220. 6 indexed citations

17.

Wang, Yili, John A. Wos, Mitchell A. deLong, et al.. (2000). Design and Synthesis of 13,14-Dihydro Prostaglandin F_1α Analogues as Potent and Selective Ligands for the Human FP Receptor. Journal of Medicinal Chemistry. 43(5). 945–952. 5 indexed citations

18.

deLong, Mitchell A., et al.. (2000). Amidation of Salicyluric Acid and Gentisuric Acid: A Possible Role for Peptidylglycine α-Amidating Monooxygenase in the Metabolism of Aspirin. Archives of Biochemistry and Biophysics. 383(1). 46–55. 15 indexed citations

19.

Ebetino, Frank H., et al.. (1999). Prostaglandin phosphonic acids through homolytic halodecarboxylation of prostaglandins F1α and F2α. Tetrahedron Letters. 40(47). 8189–8192. 3 indexed citations

20.

Baumgart, Megan, Dale L. Boger, Mitchell A. deLong, et al.. (1999). N-Acylglycine Amidation: Implications for the Biosynthesis of Fatty Acid Primary Amides. Biochemistry. 38(11). 3235–3245. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact